Exelixis Moves Into Metabolic Disease

Jul 26, 2001

NEW YORK, July 26 – Exelixis is expanding its internal drug discovery efforts into metabolic diseases, including cardiovascular disease, diabetes, and obesity, the company said Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

UPDATE: Thermo Fisher's NSCLC Companion Dx Covered by Regence BCBS
Genedrive, Sysmex Europe Sign EMEA Distribution Agreement for HCV Test, MDx Platform
Top Five Articles on GenomeWeb Last Week: GWAS of Pigmentation; ctDNA for Immunotherapy Response
In Brief This Week: 10x Genomics, Rosetta Genomics, Elsevier, and More
People in the News: Tom Civik, Thomas Grogan, Greg Yap, More
NIH to Fund Cancer MDx Development Projects

The Scan

Science Power and Research Fraud

The New York Times reports that as China invests in science, it also is dealing with research fraud.

This Week in PLOS

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Just Spread Out Here

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Tianyuan Man's Genome

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

Main menu